Tilray gains INFARMED approval for in‑house cannabis quality testing in Portugal
Portugal’s medicines regulator, INFARMED, authorized Tilray Medical’s laboratory at its Cantanhede site to perform microbiological and chemical/physical analyses internally. The company said the permission will let it release products faster and cut expenses by avoiding external labs. President Rajnish Ohri highlighted the added speed, control and flexibility for the global supply chain.
Why it matters
Tilray expects the new testing capability to lower batch‑release costs and shorten the time from harvest to market, which could improve operating efficiency in its European operations. The change may also make the company more competitive in regulated markets such as Germany and the United Kingdom.
Key facts
- 1INFARMED approved the Cantanhede laboratory to conduct microbiological and chemical/physical testing in‑house. investing.com
- 2The Cantanhede facility is an EU‑GMP‑certified production and distribution center for medical cannabis. investing.com
- 3Rajnish Ohri, President of International at Tilray Brands, said the approval gives greater speed, control and flexibility across the international supply chain. investing.com
- 4Tilray Medical supplies products to regulated markets including Germany, the United Kingdom, Poland and Italy. rttnews.com
- 5Tilray’s stock closed at $3.36, down 5.08%, after the announcement. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.